BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 32487648)

  • 21. Gas6-Axl signaling in presence of Sunitinib is enhanced, diversified and sustained in renal tumor cells, resulting in tumor-progressive advantages.
    Gustafsson A; Fritz HKM; Dahlbäck B
    Exp Cell Res; 2017 Jun; 355(1):47-56. PubMed ID: 28327411
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression of tyrosine kinase receptor AXL is associated with worse outcome of metastatic renal cell carcinomas treated with sunitinib.
    Zucca LE; Morini Matushita MA; da Silva Oliveira RJ; Scapulatempo-Neto C; de Lima MA; Ribeiro GG; Viana CR; Cárcano FM; Reis RM
    Urol Oncol; 2018 Jan; 36(1):11.e13-11.e21. PubMed ID: 28986088
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sunitinib activates Axl signaling in renal cell cancer.
    van der Mijn JC; Broxterman HJ; Knol JC; Piersma SR; De Haas RR; Dekker H; Pham TV; Van Beusechem VW; Halmos B; Mier JW; Jiménez CR; Verheul HM
    Int J Cancer; 2016 Jun; 138(12):3002-10. PubMed ID: 26815723
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The AXL receptor tyrosine kinase is associated with adverse prognosis and distant metastasis in esophageal squamous cell carcinoma.
    Hsieh MS; Yang PW; Wong LF; Lee JM
    Oncotarget; 2016 Jun; 7(24):36956-36970. PubMed ID: 27172793
    [TBL] [Abstract][Full Text] [Related]  

  • 25. AXL is a key regulator of inherent and chemotherapy-induced invasion and predicts a poor clinical outcome in early-stage colon cancer.
    Dunne PD; McArt DG; Blayney JK; Kalimutho M; Greer S; Wang T; Srivastava S; Ong CW; Arthur K; Loughrey M; Redmond K; Longley DB; Salto-Tellez M; Johnston PG; Van Schaeybroeck S
    Clin Cancer Res; 2014 Jan; 20(1):164-75. PubMed ID: 24170546
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Axl-Regulating Tumor Suppressor miR-34a Is Increased in ccRCC but Does Not Correlate with Axl mRNA or Axl Protein Levels.
    Fritz HK; Gustafsson A; Ljungberg B; Ceder Y; Axelson H; Dahlbäck B
    PLoS One; 2015; 10(8):e0135991. PubMed ID: 26287733
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Feline sarcoma-related protein expression correlates with malignant aggressiveness and poor prognosis in renal cell carcinoma.
    Miyata Y; Kanda S; Sakai H; Greer PA
    Cancer Sci; 2013 Jun; 104(6):681-6. PubMed ID: 23445469
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Axl Expression Stratifies Patients with Poor Prognosis after Hepatectomy for Hepatocellular Carcinoma.
    Liu J; Wang K; Yan Z; Xia Y; Li J; Shi L; Zou Q; Wan X; Jiao B; Wang H; Wu M; Zhang Y; Shen F
    PLoS One; 2016; 11(5):e0154767. PubMed ID: 27182739
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expression of molecular markers associated with the mammalian target of rapamycin pathway in nonmetastatic renal cell carcinoma: Effect on prognostic outcomes following radical nephrectomy.
    Nishikawa M; Miyake H; Harada K; Fujisawa M
    Urol Oncol; 2014 Jan; 32(1):49.e15-21. PubMed ID: 24239474
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Low level of isocitrate dehydrogenase 1 predicts unfavorable postoperative outcomes in patients with clear cell renal cell carcinoma.
    Laba P; Wang J; Zhang J
    BMC Cancer; 2018 Aug; 18(1):852. PubMed ID: 30153799
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification and validation of novel prognostic markers in Renal Cell Carcinoma.
    Rabjerg M
    Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975890
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Landscape of prognostic signatures and immunogenomics of the AXL/GAS6 axis in renal cell carcinoma.
    Hakozaki K; Tanaka N; Takamatsu K; Takahashi R; Yasumizu Y; Mikami S; Shinojima T; Kakimi K; Kamatani T; Miya F; Tsunoda T; Aimono E; Nishihara H; Mizuno R; Oya M
    Br J Cancer; 2021 Nov; 125(11):1533-1543. PubMed ID: 34611307
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CXC chemokine receptor 2 is associated with postoperative recurrence and survival of patients with non-metastatic clear-cell renal cell carcinoma.
    An H; Xu L; Chang Y; Zhu Y; Yang Y; Chen L; Lin Z; Xu J
    Eur J Cancer; 2015 Sep; 51(14):1953-61. PubMed ID: 26188847
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interleukin-11 receptor predicts post-operative clinical outcome in patients with early-stage clear-cell renal cell carcinoma.
    Pan D; Xu L; Liu H; Zhang W; Zhu Y; Xu J; Gu J
    Jpn J Clin Oncol; 2015 Feb; 45(2):202-9. PubMed ID: 25420690
    [TBL] [Abstract][Full Text] [Related]  

  • 35. C-reactive protein in patients with advanced metastatic renal cell carcinoma: usefulness in identifying patients most likely to benefit from initial nephrectomy.
    Ito H; Shioi K; Murakami T; Takizawa A; Sano F; Kawahara T; Mizuno N; Makiyama K; Nakaigawa N; Kishida T; Miura T; Kubota Y; Yao M
    BMC Cancer; 2012 Aug; 12():337. PubMed ID: 22857740
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Kidney cancer: AXL RTK--a therapeutic target in RCC?
    Stone L
    Nat Rev Urol; 2015 Sep; 12(9):475. PubMed ID: 26238031
    [No Abstract]   [Full Text] [Related]  

  • 37. High Expression of Colony-Stimulating Factor 1 Receptor Associates with Unfavorable Cancer-Specific Survival of Patients with Clear Cell Renal Cell Carcinoma.
    Yang L; Liu Y; An H; Chang Y; Zhang W; Zhu Y; Xu L; Xu J
    Ann Surg Oncol; 2016 Mar; 23(3):1044-52. PubMed ID: 26467457
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Relationship Between Increased Expression of the Axl/Gas6 Signal Cascade and Prognosis of Patients with Upper Tract Urothelial Carcinoma.
    Hattori S; Kikuchi E; Kosaka T; Miyazaki Y; Tanaka N; Miyajima A; Mikami S; Oya M
    Ann Surg Oncol; 2016 Feb; 23(2):663-70. PubMed ID: 26350366
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clear Cell Renal Cell Carcinoma is linked to Epithelial-to-Mesenchymal Transition and to Fibrosis.
    Landolt L; Eikrem Ø; Strauss P; Scherer A; Lovett DH; Beisland C; Finne K; Osman T; Ibrahim MM; Gausdal G; Ahmed L; Lorens JB; Thiery JP; Tan TZ; Sekulic M; Marti HP
    Physiol Rep; 2017 Jun; 5(11):. PubMed ID: 28596300
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Higher expression of topoisomerase II alpha is an independent marker of increased risk of cancer-specific death in patients with clear cell renal cell carcinoma.
    Parker AS; Eckel-Passow JE; Serie D; Hilton T; Parasramka M; Joseph RW; Wu KJ; Cheville JC; Leibovich BC
    Eur Urol; 2014 Nov; 66(5):929-35. PubMed ID: 24388441
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.